-transparent.png){kind=logo}
Cyclosporin is an immunosuppressive agent commonly used in transplant patients. It is actively metabolised by the cytochrome P450 system and interactions with drugs metabolised by the same system are predictable. This is particularly relevant since cyclosporin has a low therapeutic index and its renal toxicity is concentration-related. Roxithromycin, a new, well-tolerated macrolide with a weak interactive profile, uses the same isoenzyme of the P450 system as cyclosporin. To evaluate its interaction potential in clinical practice, 8 heart transplant recipients treated with cyclosporin for at least 1 month received roxithromycin for 11 days (150 mg twice daily). Bi-weekly controls of plasma cyclosporin concentrations and creatinine levels were carried out before, during and after roxithromycin treatment. A slight nonsignificant rise in cyclosporin concentrations was observed, but creatinine levels remained stable during roxithromycin treatment. Values of cyclosporin concentrations diminished after withdrawal of roxithromycin. Cyclosporin dosage adjustment was not necessary. There was a minor pharmacokinetic interaction, which can be considered safe for the usual therapeutic dosage of roxithromycin used.
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
January 1997,
European journal of clinical pharmacology,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
April 1989,
British journal of clinical pharmacology,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
July 1998,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
October 1996,
QJM : monthly journal of the Association of Physicians,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
January 1986,
European journal of clinical pharmacology,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
October 1994,
The Medical journal of Australia,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
October 1987,
Presse medicale (Paris, France : 1983),
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
April 1995,
International journal of clinical pharmacology and therapeutics,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
January 1994,
European journal of clinical pharmacology,
E M Billaud, and
R Guillemain, and
N Fortineau, and
M D Kitzis, and
G Dreyfus, and
C Amrein, and
C Kreft-Jaïs, and
J M Husson, and
P Chrétien
October 1985,
Archives des maladies du coeur et des vaisseaux,
